secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001178913-25-003248
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion selects CRO AMS for SIL204 Phase 2/3 trials; H1 2026 start expected
----------------------------------------------------------------------------

- CRO AMS has over 28 years of drug development experience and Phase 3 oncology trial expertise.
- Regulatory submissions planned for Q4 2025 (Israel) and Q1 2026 (EU).
- Phase 2/3 clinical trials for SIL204 expected to commence in first half of 2026.
- SIL204 previously showed up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003248/0001178913-25-003248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003248/zk2533756.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer